TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04428996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Description: The social cognition and interaction training (SCIT) is a manual-guide group intervention that can apply to people with serious mental illness. There have been evidences showing that the SCIT could improve emotional perception, theory of mind, attribution bias, and social relationship.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Description: The social cognition and interaction training (SCIT) is a manual-guide group intervention that can apply to people with serious mental illness. There have been evidences showing that the SCIT could improve emotional perception, theory of mind, attribution bias, and social relationship.
Study: NCT03210324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone tablets
Description: Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone tablets
Description: Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone tablets
Description: Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
Study: NCT04097509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFG application on palatinal wound healing
Description: 9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: i-PRF application on palatinal wound healing
Description: 10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no application
Study: NCT02586467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulatory Efficacy
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain-Framed + Self-Regulatory Efficacy
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss-Framed + Self-Regulatory Efficacy
Description: Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
Study: NCT00905294

Intervention type: OTHER
Intervention: Blood draws
Description: Observational: blood draws only
Study: NCT01705366

Intervention type: PROCEDURE
Intervention: Non-MAKO® Robot Assisted Total Knee Arthroplasty
Description: Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.

Intervention type: PROCEDURE
Intervention: MAKO® Robot Assisted Medial Knee Arthroplasty
Description: Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.

Intervention type: PROCEDURE
Intervention: MAKO® Robot Assisted Medial and PF Knee Arthroplasty
Description: Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee

Intervention type: DEVICE
Intervention: RESTORIS Multicompartmental Knee System
Description: The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.

Intervention type: DEVICE
Intervention: Depuy Knee Replacement System
Description: The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.

Intervention type: DEVICE
Intervention: Stryker® Knee Replacement System
Description: The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
Study: NCT03755115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin plus SHR1210
Description: First intravenous injection of epirubicin injection, D1,30mg/m\^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m\^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
Study: NCT01299285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally
Study: NCT02027584

Intervention type: OTHER
Intervention: collection of remnant of clinically indicated blood sample
Description: collection of remnant of clinically indicated blood sample

Intervention type: OTHER
Intervention: collection of remnant of clinically indicated blood sample
Description: collection of remnant of clinically indicated blood sample

Intervention type: OTHER
Intervention: collection of remnant of clinically indicated blood sample
Description: collection of remnant of clinically indicated blood sample

Intervention type: OTHER
Intervention: collection of remnant of clinically indicated blood sample
Description: collection of remnant of clinically indicated blood sample
Study: NCT04179526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet-delivered REBT
Description: The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
Study: NCT03903978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~1. Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~2. Autonomy, building my way: Enhancement of autonomy~3. Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~4. Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~5. Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~6. Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle
Description: 1. Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~2. Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~3. Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~4. Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health.
Study: NCT00486954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 6 pills at 250 mg each once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Infusion at 80 mg/m2 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Infusion at 80 mg/m2 weekly
Study: NCT01255800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-926 and Cetuximab
Description: * Patients will receive Cetuximab IV every week.~* Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day.
Study: NCT01482325

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor
Description: 10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
Study: NCT01751295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI
Study: NCT02983721

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transradial
Description: transradial route for coronary angiography and PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transradial
Description: transradial route for coronary angiography and PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral
Description: transfemoral route for coronary angiography and PCI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral
Description: transfemoral route for coronary angiography and PCI
Study: NCT00286026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children \> 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
Study: NCT00768755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5mg BID po up to max 10mg BID po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: 5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
Study: NCT01967394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of internet based social marketing intervention
Description: Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No use of social media
Description: No social media ads will be available in these counties.
Study: NCT02323945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIH
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AIH
Description: Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walk
Description: 30 minutes of walking practice consisting of 5 repetitions of 6-minute walks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength
Description: 30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
Study: NCT02050815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Study: NCT00670488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
Study: NCT00780793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progressive spacing of TNF-blocker injections
Description: Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~* if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~* if DAS28 \> 2.6 and DAS28 change ≤ 0.6: continue at step N~* if DAS28 \> 2.6 and DAS28 change \> 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~* Adalimumab 40 mg / 14 days~* Etanercept 50 mg / 7 days~Step 1 :~* Adalimumab 40 mg / 21 days~* Etanercept 50 mg / 10 days~Step 2 :~* Adalimumab 40 mg / 28 days~* Etanercept 50 mg / 14 days~Step 3 :~* Adalimumab 40 mg / 42 days~* Etanercept 50 mg / 21 days~Step 4 :~* TNF-blocker stop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARD maintenance
Description: DMARD maintenance
Study: NCT00851513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: local anesthetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anesthetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: local anesthetics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depmedrol
Description: local steroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depmedrol
Description: local steroids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiological serum
Description: important volumes of physiological serum
Study: NCT03142932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized carbon monoxide (iCO) monitor
Description: a personal monitor for a breath test for carbon monoxide (CO)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COach2Quit smartphone application
Description: This smartphone application works in conjunction with the iCO monitor

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation counseling
Description: The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cessation counseling
Description: The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
Study: NCT01750788

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
Study: NCT01305044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih
Description: Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
Study: NCT00643409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR (Zithromax; compound: CP-62,993)
Description: Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levofloxacin
Description: levofloxacin 500 mg capsule by mouth qd x 10 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo